GMG

Graphene Manufacturing Group Ltd. Commences Trading on OTCQX Under the Symbol GMGMF

Retrieved on: 
Monday, February 26, 2024

Vancouver, BC, Feb 26, 2024 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce it begins trading today on the OTCQX(R) market under the symbol "GMGMF".

Key Points: 
  • Vancouver, BC, Feb 26, 2024 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce it begins trading today on the OTCQX(R) market under the symbol "GMGMF".
  • To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/8082/199208_b72d0c1064e979c2_001fu...
    The OTCQX Best Market is for established, investor-focused U.S. and international companies.
  • GMG has now qualified to trade on the OTCQX Best Market, having been upgraded from the Pink(R) market.
  • The two lower-tier markets for OTC trading in the U.S. are the OTCQB Venture Market and the OTC Pink market.

Graphene Manufacturing Group ISO 9001:2015 Certification, Demonstrating Commitment to Quality Management

Retrieved on: 
Tuesday, February 20, 2024

This achievement underscores GMG's commitment to providing its customers with the highest quality products and services, while continuously improving its internal processes.

Key Points: 
  • This achievement underscores GMG's commitment to providing its customers with the highest quality products and services, while continuously improving its internal processes.
  • The ISO 9001 certification process involved a rigorous assessment of GMG's quality management system, covering all aspects of its operations, from customer service to production, delivery, and technical support.
  • The benefits of ISO 9001 certification for GMG include:
    - Enhanced customer satisfaction through improved product and service quality.
  • GMG is committed to maintaining its ISO 9001 certification and continuously improving its quality management system.

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Thursday, March 7, 2024

“We are opening a new chapter for the VYVGART portfolio,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx.

Key Points: 
  • “We are opening a new chapter for the VYVGART portfolio,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx.
  • These positive data from the ADHERE study have been submitted to the FDA for potential approval of VYVGART Hytrulo in CIDP with a PDUFA target action date of June 21, 2024.
  • Achievement of MSE enables significant quality of life improvements: ADAPT/ADAPT+ demonstrate that >40% of patients achieve minimal symptom expression (MSE) across both studies.
  • Patients achieving MSE experience quality of life outcomes comparable to healthy populations, suggesting MSE could be a primary goal of gMG treatment.

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Retrieved on: 
Thursday, February 29, 2024

“argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • Clinically, we generated significant data through multiple study readouts, achieving key milestones for both the CIDP and MMN patient communities and importantly advancing our second molecule, empasiprubart.
  • Looking forward to 2024, we will act with a continued sense of purpose to expand our patient reach.
  • In addition, argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS).

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

Retrieved on: 
Monday, February 26, 2024

NEW YORK and WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the initiation of the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis. The initiation follows U.S. Food and Drug Administration (FDA) clearance of the Phase 2 Investigational New Drug (IND) application for DNTH103. Top-line results from this trial are anticipated in the second half of 2025.

Key Points: 
  • The initiation follows U.S. Food and Drug Administration (FDA) clearance of the Phase 2 Investigational New Drug (IND) application for DNTH103.
  • Top-line results from this trial are anticipated in the second half of 2025.
  • “Following our encouraging Phase 1 data demonstrating a 60-day half-life and potent, specific classical pathway inhibition, we are excited to rapidly advance DNTH103, our investigational active C1s inhibitor, into a Phase 2 study in generalized Myasthenia Gravis,” said Simrat Randhawa, M.D., Chief Medical Officer of Dianthus Therapeutics.
  • Secondary endpoints include Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) and Quantitative Myasthenia Gravis (QMG) score assessments.

OTC Markets Group Welcomes Graphene Manufacturing Group Ltd. to OTCQX

Retrieved on: 
Monday, February 26, 2024

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Graphene Manufacturing Group Ltd. (“GMG”) (TSX-V: GMG; OTCQX: GMGMF), a clean-technology company focused on graphene production and development, and the manufacture and sale of graphene-based energy savings and storage products, has qualified to trade on the OTCQX® Best Market.

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Graphene Manufacturing Group Ltd. (“GMG”) (TSX-V: GMG; OTCQX: GMGMF), a clean-technology company focused on graphene production and development, and the manufacture and sale of graphene-based energy savings and storage products, has qualified to trade on the OTCQX® Best Market.
  • Graphene Manufacturing Group Ltd. upgraded to OTCQX from the Pink® market.
  • Graphene Manufacturing Group Ltd. begins trading today on OTCQX under the symbol “GMGMF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com .
  • Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors.

"All United for MG" coalition launches a petition to advocate change in Myasthenia Gravis

Retrieved on: 
Wednesday, March 6, 2024

BRUSSELS, March 6, 2024 /PRNewswire/ -- Following Rare Disease Day and in anticipation of the European elections, All United for MG has undertaken the initiative to mobilize society, initiating transformative changes for the patient community. Since its establishment in 2023, All United for MG has been amplifying the generalised Myasthenia Gravis (gMG) patient voice across Europe. A Call for Action, launched with European parliamentarians Tomislav Sokol and Istvan Ujhelyi in June 2023 during the first-ever Myasthenia Gravis Day, contains six actionable policy recommendations for the improvement of the visibility, recognition and treatment of Myasthenia Gravis (MG) and other rare diseases. These recommendations were supported by over 30 stakeholders, including 11 members of the European Parliament, healthcare professionals and Patient Advocacy Groups (PAGs). All United for MG is now intensifying its efforts and seeks the support of all citizens across Europe by launching a petition on change.org, to encourage the civil society to support and advocate for changes in the management of rare diseases care,especially in generalized Myasthenia Gravis (gMG). The ambition is to collect between 5.000 - 10.000 signatures in the lead-up to the second Myasthenia Gravis Awareness Day on June 2nd and the European elections. 

Key Points: 
  • In the context of Autoimmune Awareness Month, the coalition of patients suffering from Myasthenia Gravis (MG) "All United for MG" urges citizens throughout Europe to unite in instigating positive change and enhancing Myasthenia Gravis management.
  • All United for MG is officially launching a European petition to advocate for better rights for patients and their caregivers, improved access to healthcare and enhanced conditions.
  • Since its establishment in 2023, All United for MG has been amplifying the generalised Myasthenia Gravis (gMG) patient voice across Europe.
  • "Rare diseases often struggle for visibility in political discourse, making the All United for MG petition all the more important.

"All United for MG" coalition launches a petition to advocate change in Myasthenia Gravis

Retrieved on: 
Wednesday, March 6, 2024

BRUSSELS, March 6, 2024 /PRNewswire/ -- Following Rare Disease Day and in anticipation of the European elections, All United for MG has undertaken the initiative to mobilize society, initiating transformative changes for the patient community. Since its establishment in 2023, All United for MG has been amplifying the generalised Myasthenia Gravis (gMG) patient voice across Europe. A Call for Action, launched with European parliamentarians Tomislav Sokol and Istvan Ujhelyi in June 2023 during the first-ever Myasthenia Gravis Day, contains six actionable policy recommendations for the improvement of the visibility, recognition and treatment of Myasthenia Gravis (MG) and other rare diseases. These recommendations were supported by over 30 stakeholders, including 11 members of the European Parliament, healthcare professionals and Patient Advocacy Groups (PAGs). All United for MG is now intensifying its efforts and seeks the support of all citizens across Europe by launching a petition on change.org, to encourage the civil society to support and advocate for changes in the management of rare diseases care,especially in generalized Myasthenia Gravis (gMG). The ambition is to collect between 5.000 - 10.000 signatures in the lead-up to the second Myasthenia Gravis Awareness Day on June 2nd and the European elections. 

Key Points: 
  • In the context of Autoimmune Awareness Month, the coalition of patients suffering from Myasthenia Gravis (MG) "All United for MG" urges citizens throughout Europe to unite in instigating positive change and enhancing Myasthenia Gravis management.
  • All United for MG is officially launching a European petition to advocate for better rights for patients and their caregivers, improved access to healthcare and enhanced conditions.
  • Since its establishment in 2023, All United for MG has been amplifying the generalised Myasthenia Gravis (gMG) patient voice across Europe.
  • "Rare diseases often struggle for visibility in political discourse, making the All United for MG petition all the more important.

GMG's Graphene Aluminium-Ion Battery Update: Minimal Temperature Rise Identified While Fast Charging

Retrieved on: 
Wednesday, February 14, 2024

The Company is pleased to announce that it has identified minimal temperature rise when charging and discharging GMG's Graphene Aluminium-Ion Battery.

Key Points: 
  • The Company is pleased to announce that it has identified minimal temperature rise when charging and discharging GMG's Graphene Aluminium-Ion Battery.
  • By comparison, GMG's Graphene Aluminium-Ion Battery temperature is 29 degrees Celsius when it is discharged at even higher current density (20 C-rate - approximately 2.0 A/g on the cathode active mass).
  • The battery technology readiness level ("BTRL") of the Graphene Aluminium-Ion technology remains at Level 4 (see Figure 4).
  • Figure 4: Graphene Aluminium Ion Battery Comparative Performance Data (for coin cells)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/197885_6af50fb874a9984b_006fu...

Western Uranium & Vanadium Mining Operations Update

Retrieved on: 
Tuesday, February 13, 2024

Toronto, Ontario and Nucla, Colorado, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Western Uranium & Vanadium Corp. (CSE: WUC) (OTCQX: WSTRF) (“Western” or the ”Company”) is pleased to offer an update on its mining operations, highlighting significant achievements and outlining strategic goals for the upcoming year.

Key Points: 
  • Toronto, Ontario and Nucla, Colorado, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Western Uranium & Vanadium Corp. (CSE: WUC) (OTCQX: WSTRF) (“Western” or the ”Company”) is pleased to offer an update on its mining operations, highlighting significant achievements and outlining strategic goals for the upcoming year.
  • Looking forward, the Company is gearing up to produce significant quantities of uranium and vanadium in 2025.
  • A successful ramp-up would achieve the annual ore production goal of 1 million pounds of uranium and 6 million pounds of vanadium.
  • Our current production ramp-up efforts are geared towards ensuring an adequate uranium feedstock supply for the Maverick Minerals Processing Plant.